RxDoctor Payments Data

Terri Speck, NP

Family Health · Fort Worth, TXNPI 1437592748

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 31 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. AbbVie accounts for 72.2% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2021 at $352 and has fallen 95.5% since, to $16 in 2024.

$424in general payments, 2019–2025

Across 31 payments — averaging $13.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$306
  • Pfizer$37
  • Merck$20
  • Biohaven Pharmaceuticals, Inc.$19
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$15
  • Takeda Pharmaceuticals U.S.A., Inc.$14
  • plus $14 from 1 others

What the payments were for

  • Food & beverage$424100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$424 in reported general payments places this provider in the 55th percentile of 23 family health providers in Texas.

See all family health providers in Texas

Medicare billing

Part B allowed, 2024
$53,721
Medicare patients
150
Services billed
5,927

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide106$185,781
EliquisApixaban44$52,803
MounjaroTirzepatide15$41,363
LinzessLinaclotide15$17,013
XareltoRivaroxaban11$15,991
SymbicortBudesonide/Formoterol Fumarate18$5,684
MyrbetriqMirabegron11$4,949
LevemirInsulin Detemir12$3,844
Omeprazole151$2,838
Gabapentin119$2,624
Atorvastatin Calcium200$2,334
Rosuvastatin Calcium190$2,094
Albuterol Sulfate HfaAlbuterol Sulfate89$2,058
Levothyroxine Sodium226$2,027
Lisinopril236$1,603

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$37$52,80344 claims
AbbVieLinzess, Synthroid$306$18,59339 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 23 family health providers in Texas.

Other family health in Fort Worth

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →